Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Actimol (citrulline malate) for fatigue and weakness during PARP inhibitor treatment in epithelial ovarian cancer
KCT0011779Phase 2Recruiting
- Sponsor
- Pharmbio Korea Inc.
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of acetaminophen in epithelial ovarian cancer (EOC), sponsored by Pharmbio Korea Inc. Started Mar 2026; status: recruiting.
02
Drugs
acetaminophen
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on KCT0011779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0011779.